The original article ‘Holdemanella biformis improves glucose tolerance and regulates GLP-1 signaling in obese mice‘ (doi: 10.1096/fj.202100126R) has recently been published in the FASEB Journal.
Its authors are Marina Romaní-Pérez, Inmaculada López-Almela, Clara Bullich-Vilarrubias, Lola Rueda-Ruzafa, Eva M Gómez Del Pulgar, Alfonso Benítez-Páez, Gerhard Liebisch, José Antonio Lamas and Yolanda Sanz Yolanda Sanz.
This work is the result of collaboration between the Microbial Ecology, Nutrition and Health unit of the IATA-CSIC, the Neuroscience group of the CINBIO (University of Vigo) and the Institute of Clinical Chemistry and Laboratory Medicine, University of Regensburg (Germany).
Here is a brief summary of its contents:
“Impaired glucose homeostasis in obesity is mitigated by enhancing the glucoregulatory actions of glucagon-like peptide 1 (GLP-1), and thus, strategies that improve GLP-1 sensitivity and secretion have therapeutic potential for the treatment of type 2 diabetes.
This study shows that Holdemanella biformis, isolated from the feces of a metabolically healthy volunteer, ameliorates hyperglycemia, improves oral glucose tolerance and restores gluconeogenesis and insulin signaling in the liver of obese mice. These effects were associated with the ability of H. biformis to restore GLP-1 levels, enhancing GLP-1 neural signaling in the proximal and distal small intestine and GLP-1 sensitivity of vagal sensory neurons, and to modify the cecal abundance of unsaturated fatty acids and the bacterial species associated with metabolic health.
Our findings overall suggest the potential use of H biformis in the management of type 2 diabetes in obesity to optimize the sensitivity and function of the GLP-1 system, through direct and indirect mechanisms.”